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hard and painful mass was palpated around the left Bartholin's gland.
Macroscopic observation revealed no abnormalities of either themuco-
sa or the vulva around the vaginal ostium. No macroscopic abnormali-
ties were observed in either the uterine cervix or the vaginal wall. The
uterus was 7×4 cm in size and highly mobile. Neither adnexa was
palpable. There was no inguinal lymphadenopathy.
Clinical examinationsclear border and an irregular internal echo pattern at the left side ofIntroduction
Malignant tumors arising in the vulva reportedly account for 3% to 5%
of gynecological malignancies, and Bartholin's gland carcinoma was
reported to account for 0.1% to 7% of vulvar malignancies (Nasu et al.,
2005). In particular, adenoid cystic carcinoma (ACC) is extremely rare,
accounting for approximately 10% of Bartholin's gland malignancies.
The tissue types of ACC vary. While its frequency is high in the salivary
gland, paranasal sinus, breast, and skin, this carcinoma is also occasionally
observed in the cervical glands and ovaries in the gynecological ﬁeld.
However, ACC of Bartholin's gland is extremely rare, with only about 80
cases having been reported in the international literature (Alsan et al.,
2011). Moreover, there is as yet no established postoperative treatment.
We experienced a case in which chemoradiotherapy with irinotecan
(CPT-11) was performed for ACC of Bartholin's gland. This case is
presented with a review of the relevant literature.
Case report
Our patient was a 68-year-old woman, gravida 3, para 2, with men-
opause at age 58 years. Family and past histories were unremarkable.
She had not undergone gynecologic cancer screening. She visited a
neighborhood hospital with a chief complaint of a painful mass that
had been present in the left vulva for one year, for which antibiotics
had been administered based on the diagnosis of an infected Bartholin
cyst. Because relief was not obtained with this treatment, she was
referred to our hospital.nd Gynecology, Iwate Medical
pan. Fax: +81 19 622 1900.
-ND license.Transvaginal ultrasonography revealed a 3.2×2.0 cm mass with a
the vaginal ostium (Fig. 1A). There were no abnormalities in either
ovary. Magnetic response imaging (MRI) revealed a 2.0×1.9 cm mass
with an irregular border and contrast enhancement around the left
Bartholin's gland (Fig. 1B). Routine hematologic and biochemical tests
revealed no abnormalities. The following tumor marker results were
obtained: CEA of 2.9 ng/mL, CA19-9 of 6.8 U/mL, and CA 125 of
19.3 U/mL, and SCC was below 0.5 ng/mL. Cervical cytology showed
no evidence of either an intraepithelial lesion or malignancy, and endo-
metrial cytology results were also negative.
Treatment course
Tumor resection was performed for treatment and diagnosis. The
tumor was located below the mucosa of the vaginal opening and
had not inﬁltrated the surrounding tissue, based on macroscopic
observation. The border was unclear, and the tumor had inﬁltrated
and proliferated within the tissue around the pubis corresponding
to the left Bartholin's gland. The resected tumor was 1.5×2.0 cm in
size, white, and hard. A honeycomb structure containing mucus was
observed inside the tumor mass (Fig. 2). The postoperative histopath-
ological diagnosis was ACC. Although continuity with the normal
Bartholin's gland was not conﬁrmed, the carcinoma was considered
to have originated in Bartholin's gland, based on the site of occur-
rence (Fig. 3). After surgery, the patient refused to undergo a detailed
lower gastrointestinal tract examination. But the patient was exam-
ined by the positron emission tomography-computed tomography
(PET-CT) and routine CT, and there was no area of abnormally
increased uptake of FDG in the whole body. Because neither PET-CT
nor routine CT revealed any potential primary lesions, the patient
was diagnosed as having ACC of Bartholin's gland. The resection
margin was positive. After obtaining her consent for postoperative
treatment, chemoradiotherapy (whole pelvis irradiation at a total
Fig. 1. A: Transvaginal ultrasonography. 3.2×2.0 cm low echo area with an irregular internal pattern was observed at the left side of the vaginal ostium. B: MRI of the pelvic cavity.
2.0×1.9 cm mass imaged with contrast enhancement corresponded to the left Bartholin's gland. The border with adjacent bone was clear.
17E. Takatori et al. / Gynecologic Oncology Reports 4 (2013) 16–19dose of 59.4 Gy in 33 fractions combined with CPT-11 at a dose of
50 mg/m2×5) was administered. Although Grade 2 neutropenia
(1024/mm3) and Grade 2 anemia (9.4 g/dL) were observed as hema-
tologic toxicities, both were manageable. Moreover, non-hematologic
toxicities were Grade 1 nausea and Grade 2 radiation dermatitis,
whereas diarrhea did not occur. For the 24 months since treatment
completion, to date, there have been no signs of recurrence.
Discussion
Bartholin's gland carcinomas account for approximately 0.1% to 7%
of vulvar malignancies (Nasu et al., 2005). However, as noted above,
ACC of Bartholin's gland has been reported in only about 80 cases in
the international literature. According to a review of 49 articles
conducted by Alsan et al., the median age of 79 cases was 48 years
(range: 25–80 years) (Alsan et al., 2011). Although no characteristic
test ﬁnding was revealed, there were many patients with a chief
complaint of a vulvar mass associated with pain and burning sensationFig. 2.Macroscopic ﬁndings of the left Bartholin's gland tumor. The resected tumor was 1.5×
within the tumor mass.of the vulvae. Thus, it is preferable to actively perform biopsy or
resection for early diagnosis in patients age 40 and older with a painful
indurated mass involving Bartholin's gland. While cases preoperatively
diagnosed by aspiration biopsy cytology have been reported, there are
also many in which this disease was deﬁnitively diagnosed after
tumor resection performed for both diagnosis and treatment. Although
no therapy has yet been established, the recommended surgical strate-
gies are simple vulvectomy, radical vulvectomy, and lymph node dis-
section to the affected inguinal lymph node. Because ACC also occurs
in relatively young women, lymph node dissection is recommended
for such patients. However, it appears that vulvectomy should be
recommended for elderly patients while lymph node dissection is not
performed given the risks of postoperative complications such as deep
venous thrombosis and lymphedema. Also, very little data are available
regarding lymph node dissection at any age for this disease. According
to the review by Alsan et al., simple and radical vulvectomy had been
performed in 54% and 46% of cases, respectively. However, the recur-
rence rate was not low. Recurrence was observed in 35% of cases with2.0 cm in size, white, and hard. A honeycomb structure containing mucus was observed
Fig. 3. A: The mass had a lobular structure and showed inﬁltrative proliferation (Hematoxylin & Eosin staining ×20). B: The tumor cells were relatively homogeneous, small and
circular to oval in shape containing a nucleus with densely stained chromatin. The nucleus-to-cytoplasm ratio was high (Hematoxylin & Eosin staining ×200). C: The tumor
cells proliferated in an alveolar pattern, forming many large and small pseudocysts, with mucus-ﬁlled lumens, and showed a cribriform pattern (Hematoxylin & Eosin staining
×100). D: The tumor cells showed inﬁltrative proliferation into the surrounding soft tissue. No perineural inﬁltration, considered to be characteristic of Bartholin's tumors, was
detected (Hematoxylin & Eosin staining ×40).
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section margins (Alsan et al., 2011). Furthermore, there are also reports
of the resection margin being positive in 48% of patients undergoing
resection of the affected vulva and 30% of those undergoing radical
vulvectomy (Yang et al., 2006). Because radical vulvectomy may sub-
stantially reduce quality of life (QOL) for patients, we advocate that
surgical procedures be selected with consideration of age. Moreover,
since ACC of Bartholin's gland also reportedly occurs even in young
woman (Korkontzelos et al., 2009), therapeutic strategies should be
carefully determined with consideration of QOL and the emotional
burden on the patient.
In cases with positive resection margins or neural inﬁltration,
postoperative radiotherapy is recommended. According to Alsan et
al., the recurrence rate was 9.5% (2/21 patients) in those undergoing
radiotherapy and 37.5% (21/56 patients) in those not receiving radio-
therapy, indicating that local recurrence was satisfactorily managed
with radiotherapy (p=0.01) (Alsan et al., 2011). However, there
are still no established guidelines for postoperative chemotherapy
and chemoradiotherapy. In 1984, Sugiyama et al. reported that
chemoradiotherapy with concomitant use of 5-ﬂuorouracil was effec-
tive (Sugiyama et al., 1984). The reported chemotherapy regimens
were methotrexate, dactinomycin, doxorubicin (DXR), cyclophospha-
mide (CPA), and CPA+DXR, CPA+DXR+cisplatin. However, all
of these regimens tend to induce substantial hematologic as well
as non-hematologic toxicities. Although the resection margin was
positive in our patient, additional resectionwas not performed at her re-
quest. Instead, chemoradiotherapy with CPT-11 was administered after
surgery. The efﬁcacy of CPT-11 for gynecological malignancies, such ascervical and ovarian cancer, has been demonstrated (Shoji et al., 2010,
2011). Regarding the use of CPT-11 for ACC treatment, there is only
one report of a patient with ACC originating from the salivary gland
who received chemotherapy with platinum and irinotecan-based
regimens (De Dosso et al., 2009). Because the tumor in our patient was
not a squamous cell carcinoma, cisplatin was not used. Moreover, con-
comitant chemoradiotherapy using 5-ﬂuorouracil was not performed
due to insufﬁcient evidence of efﬁcacy for gynecological cancers. Because
the adverse events associated with CPT-11 are manageable, and the
efﬁcacy of CPT-11 for gynecological malignancies, especially adenocarci-
noma, has been established, we selected this regimen for our present pa-
tient. She was able to complete CPT-11 (50 mg/m2) administration 5
times eachweek, with no delays or skipping of doses. The adverse events
were manageable. QOL was maintained throughout treatment.
ACC is slow-growing, with a 5-year survival rate of 71% to 100%
and a 10-year survival rate of 59% to 100%. Thus, long-term survival
can be expected (Lelle et al., 1994). However, cases with hematoge-
nous distant metastasis occurring after a long disease-free period
have also been reported (Hatiboglu et al., 2005). The disease-free
survival rates are 47% to 83% at 5 years and 33% to 38% at 10 years
(Woida and Ribeiro-Silva, 2007). For patients who are elderly
at the onset of this disease, a therapy with few adverse reactions
should be selected. This is the ﬁrst report, to our knowledge, on
chemoradiotherapy with CPT-11 for ACC of Bartholin's gland as post-
operative treatment. There is an urgent need to establish appropriate
adjuvant therapy for rare ACC of Bartholin's gland. We hope that this
report will promote the establishment of effective therapy for ACC of
Bartholin's gland.
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